# Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer

> **NCT02154737** · PHASE1 · COMPLETED · sponsor: **Tony Reid, M.D., Ph.D.** · enrollment: 24 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT02154737
- **Lead sponsor:** Tony Reid, M.D., Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2020-09-03
- **Final completion:** 2020-09-03
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2021-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02154737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02154737, "Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02154737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*